Aceclofenac is a Small Molecule owned by Almirall, and is involved in 2 clinical trials, which were completed. Aceclofenac acts by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase (COX-1 and COX-2), which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of aceclofenac.
The revenue for Aceclofenac is expected to reach a total of $185m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Aceclofenac NPV Report.
Aceclofenac is currently owned by Almirall.
Aceclofenac (Airtal, Aertal, Cartrex, Palison, Kafenac, Preservex, Gerbin Gladio, Beofenac, Falcol, Bristaflam) is a phenylacetic acid derivative acts as a non-steroidal anti-inflammatory agent. It is formulated as film coated tablets, powder for suspension for oral route of administration, suppositories for rectal route, cream for topical application and solution for intramuscular route of administration. Aceclofenac is indicated for the treatment of chronic bone and joint disorders such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and rheumatism extra such as joint periarthritis, tendinitis, bursitis, enthesitis, acute painful conditions of different etiology such as sciatica, back pain, muscle pain, primary dysmenorrhea, pain consequent to trauma of various kinds, and odontalgia.
Almirall is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.
The company reported revenues of (Euro) EUR827.2 million for the fiscal year ended December 2021 (FY2021), an increase of 2.4% over FY2020. In FY2021, the company’s operating margin was 0.7%, compared to an operating margin of 11.4% in FY2020. The net loss of the company was EUR40.9 million in FY2021, compared to a net profit of EUR74.3 million in FY2020. The company reported revenues of EUR197.2 million for the third quarter ended September 2022, a decrease of 54.8% over the previous quarter.
Quick View – Aceclofenac
|Highest Development Stage|